HEALTH CANADA

Their core work

Health Canada is Canada's federal health regulatory authority, responsible for setting national standards for the safety of health products, chemicals, radiation, and environmental contaminants. In EU research projects, it contributes its regulatory science expertise — specifically risk assessment frameworks, exposure modelling, and dosimetry — as an international third-party partner. Its participation in RadoNorm and CompSafeNano reflects its dual mandate in radiation protection policy and emerging substance regulation, including nanomaterials. For consortium partners, Health Canada brings the authoritative Canadian regulatory perspective, which is particularly valuable when research aims at policy translation or international standard-setting.

What they specialise in

How they've shifted over time

Health Canada entered H2020 collaboration in 2020 via RadoNorm, focusing on the physical and social dimensions of radiation risk — exposure quantification, dosimetry, health effects, and public communication. By 2021, its second engagement shifted to the emerging field of nano-risk, with a computational and predictive orientation: nanoinformatics, nanoform characterisation, and safe-by-design. This short two-project timeline shows a clear pivot from classical physical-agent risk (radiation) toward chemical-agent risk in the nano domain, both grounded in the same underlying regulatory science methodology.

Health Canada is moving toward computational risk assessment for novel substances, suggesting future collaborations are most likely in digital toxicology, predictive nanosafety, and regulatory harmonisation between Canada and the EU.

How they like to work

Health Canada participates exclusively as a third-party contributor — never as project coordinator — which is consistent with its status as a non-EU government body operating under MSCA-RISE and RIA rules. It joins large, multi-country consortia (81 partners across 31 countries across just two projects), contributing regulatory authority credibility rather than laboratory capacity. For potential collaborators, this means Health Canada is a high-legitimacy scientific validator and policy bridge, not a hands-on project manager.

Despite only two H2020 projects, Health Canada has co-participated with 81 unique partner organisations across 31 countries — indicating involvement in very large flagship consortia with broad international reach. Its network spans primarily European institutions with explicit international partnership links, reflecting the MSCA-RISE mobility scheme in CompSafeNano.

What sets them apart

Health Canada is the only Canadian federal regulatory authority active in H2020, which gives it a singular position as a bridge between EU research and North American regulatory acceptance. Where most research organisations bring laboratory or modelling capacity, Health Canada brings regulatory authority: its involvement signals that a project's outputs are being validated against real-world national standards. For consortia targeting policy impact or seeking international credibility beyond Europe, this is a rare asset.

Highlights from their portfolio

• CompSafeNano
  A 2021–2026 MSCA-RISE project applying nanoinformatics to safe-by-design nanomaterials, where Health Canada's role bridges EU nano-regulation research with Canadian federal substance safety standards.
• RadoNorm
  A large 2020–2025 RIA consortium addressing radiation protection policy reform across 31+ countries, with Health Canada contributing dosimetry and exposure expertise from a non-EU regulatory perspective.